Stock Track | GENSCRIPT BIO Soars 14.99% Intraday on Positive Clinical Data from Associate Legend Biotech

Stock Track

06/03

GENSCRIPT BIO (01548) experienced a significant intraday surge, with its stock price soaring 14.99% at the market open on Wednesday.

The sharp increase was primarily driven by positive preliminary clinical data announced by its associate company, Legend Biotech. Legend reported encouraging results for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

The promising data, which is scheduled for a late-breaking oral presentation at the upcoming European Hematology Association (EHA) 2026 Congress, triggered a more than 42% jump in Legend Biotech's US-listed shares overnight. This positive sentiment directly impacted GENSCRIPT BIO, as the market reacted to the potential progress in this innovative CAR-T therapy developed using Legend's proprietary TaVec™ platform.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1135256638"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135256638\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135256638?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135256638","market":"us","top_or_hot":-1,"title":"Stock Track | GENSCRIPT BIO Soars 14.99% Intraday on Positive Clinical Data from Associate Legend Biotech","media":"Stock Track","content":"<p>GENSCRIPT BIO (01548) experienced a significant intraday surge, with its stock price soaring 14.99% at the market open on Wednesday.</p><p>The sharp increase was primarily driven by positive preliminary clinical data announced by its associate company, Legend Biotech. Legend reported encouraging results for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.</p><p>The promising data, which is scheduled for a late-breaking oral presentation at the upcoming European Hematology Association (EHA) 2026 Congress, triggered a more than 42% jump in Legend Biotech's US-listed shares overnight. This positive sentiment directly impacted GENSCRIPT BIO, as the market reacted to the potential progress in this innovative CAR-T therapy developed using Legend's proprietary TaVec™ platform.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENSCRIPT BIO Soars 14.99% Intraday on Positive Clinical Data from Associate Legend Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENSCRIPT BIO Soars 14.99% Intraday on Positive Clinical Data from Associate Legend Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-03 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) experienced a significant intraday surge, with its stock price soaring 14.99% at the market open on Wednesday.</p><p>The sharp increase was primarily driven by positive preliminary clinical data announced by its associate company, Legend Biotech. Legend reported encouraging results for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.</p><p>The promising data, which is scheduled for a late-breaking oral presentation at the upcoming European Hematology Association (EHA) 2026 Congress, triggered a more than 42% jump in Legend Biotech's US-listed shares overnight. This positive sentiment directly impacted GENSCRIPT BIO, as the market reacted to the potential progress in this innovative CAR-T therapy developed using Legend's proprietary TaVec™ platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1135256638","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135256638","pubTimestamp":1780450315,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GENSCRIPT BIO (01548) experienced a significant intraday surge, with its stock price soaring 14.99% at the market open on Wednesday.The sharp increase was primarily driven by positive preliminary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"个股追踪|金斯瑞生物盘中大涨14.99%因联营企业传奇生物临床数据利好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO (01548) experienced a significant intraday surge, with its stock price soaring 14.99% at the market open on Wednesday.The sharp increase was primarily driven by positive preliminary clinical data announced by its associate company, Legend Biotech. Legend reported encouraging results for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.The promising data, which is scheduled for a late-breaking oral presentation at the upcoming European Hematology Association (EHA) 2026 Congress, triggered a more than 42% jump in Legend Biotech's US-listed shares overnight. This positive sentiment directly impacted GENSCRIPT BIO, as the market reacted to the potential progress in this innovative CAR-T therapy developed using Legend's proprietary TaVec™ platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}